Value of Geriatric Assessment in Patients With Genitourinary Carcinoma
October 19, 2021

This work from Quirin Zangle, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.

Pseudoprogression in Melanoma Therapy
October 19, 2021

John Kirkwood, MD, PhD, addresses the idea of pseudoprogression seen in melanoma therapy.

Monitoring Responses to Melanoma Therapy
October 19, 2021

An expert in melanoma cancer treatment relays the monitoring options for melanoma therapy and gives advice for how long these therapies should be monitored.

Luciano Costa, MD, PhD, Shares Key Takeaways From the MASTER Trial in Multiple Myeloma
October 19, 2021

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.

How the Emergence of Immunotherapy has Impacted Practice Patterns for Treatment and Management of Merkel Cell Carcinoma
October 19, 2021

A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.

Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer
October 19, 2021

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

Scott T. Tagawa, MD, MS, on Compelling ESMO Data for Metastatic Castration-Sensitive Prostate Cancer
October 18, 2021

Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.

Monitoring Response to Therapy in NSCLC
October 18, 2021

Dr Roy Herbst reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Treatment Options in Non–Small-Cell Lung Cancer (NSCLC)
October 18, 2021

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

KRd Plus Lenalidomide Maintenance Yielded Positive MRD- CRs and May Delay End-Organ Disease in High-Risk Smoldering Myeloma
October 18, 2021

Patients with high-risk smoldering myeloma who were treated with carfilzomib, lenalidomide, and dexamethasone and lenalidomide maintenance experienced an improvement in minimal residual disease–negative complete response and could have delayed end-organ disease.